Adherium Conversation Series: Transforming COPD care through remote monitoring

/in ,

Adherium Conversation Series: Transforming COPD care through remote monitoring With 46 years of respiratory therapy experience, Kimberly Bennion, MsHS, RRT, CHC, FAARC, is leading the Intermountain COPD and Adult Asthma Remote Evaluation Study, a groundbreaking USD $5M research initiative focused on improving care for vulnerable pulmonary patients. Using Adherium’s Hailie® Smartinhaler® technology, Kimberly’s team is […]

Read more

Phase 2 clinical trial of CYP-001 for treating high risk acute graft-versus-host disease

/in ,

Phase 2 clinical trial of CYP-001 for treating high risk acute graft-versus-host disease Earlier this week at the Australia and New Zealand Cellular Therapy and Transplant Conference (ANZTCT), Dr Ashleigh Scott of Cynata Therapeutics presented their latest clinical progress: a Phase 2 randomised, double-blind, placebo-controlled trial of CYP-001 for high-risk acute graft-versus-host disease (HR-aGvHD). CYP-001, manufactured with its proprietary Cymerus® technology, delivers consistent, high-quality […]

Read more

Licensing partnership in Saudi Arabia for Dapsone 5% Gel

/in ,

Licensing partnership in Saudi Arabia for Dapsone 5% Gel Melbourne, Australia; 31 July 2025; Acrux Limited (ASX: ACR) Acrux has executed a Sales, Marketing, Distribution and License Agreement with Servacure Trading W.L.L. (‘Servacure’) for Dapsone 5%, Gel for Saudi Arabia. Dapsone 5%, Gel was developed Acrux and was successfully launched through a licensee in […]

Read more

Adherium conducts A$0.35m placement to institutional investor

/in ,

Adherium conducts A$0.35m placement to institutional investor Summary: Firm commitments received for A$0.35M institutional placement (before costs) at A$0.005 per share The proceeds, together with existing cash reserves and proceeds from the recent ANREO will allow Adherium toexecute on its growth plan and provide balance sheet strength. Melbourne, Australia – 4 August 2025: is pleased to announce that it has received firm commitments from sophisticated and professional investors to raise approximately A$0.35M (before costs) through an institutional placement (the “Placement”). The Placement was undertaken on the same terms as the recent partially underwritten […]

Read more